Search This Blog

Monday, March 6, 2023

BioVie: More Positive Findings from Phase 2 Parkinson’s Trial

 BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced additional preliminary findings from its Parkinson’s Disease (PD) Phase 2 trial. The preliminary findings show that significantly more patients treated with the Company’s drug, NE3107, were assessed as being in the “ON” state in the morning after withholding their usual standard of care (SOC) for at least 8 hours before taking their usual morning Parkinson’s medications, compared to patients on SOC alone plus placebo (p<0.02).

Many PD patients complain of having rigid muscles and difficulties getting out of bed in the morning, which is referred to as the muscles being in an “off state.” Conversely, patients are considered to be in the “on state” if they retain sufficient muscle control. The “on state” is clinically meaningful for PD patients because it is the time when their motor symptoms are most optimally controlled, allowing for better movement and stability.

https://finance.yahoo.com/news/biovie-announces-additional-findings-phase-130000852.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.